Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,864 across all filing types
Latest filing 2019-02-14 Major Shareholding Noti…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
SC 13G/A Filing
Major Shareholding Notification
2019-02-14 English
SC 13G Filing
Major Shareholding Notification
2019-02-12 English
Evotec and Galapagos enter into collaboration in the field of fibrosis/ Evotec en Galapagos gaan samenwerking aan in fibrose
M&A Activity Classification · 99% confidence The document is a press release dated February 7, 2019, announcing a global collaboration between Evotec and Galapagos regarding a new target for fibrosis. It details the terms of the agreement, including licensing fees, milestones, royalties, and responsibilities for further development. This type of announcement, detailing a strategic partnership, drug development collaboration, or significant corporate agreement that involves future financial considerations (milestones/royalties), fits best under the category of Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a mandatory disclosure without a better fit. However, since it describes a major business transaction involving the acquisition of commercialization rights and future payments, it is most closely aligned with corporate financing/deal activity. Given the options, 'CAP' (Capital/Financing Update) covers significant business deals and fundraising activities. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific announcement, not a general regulatory filing fallback (RNS), unless the deal itself mandates a specific regulatory filing not listed. Since it details a major strategic transaction, CAP is the most appropriate fit among the provided specific codes.
2019-02-07 Dutch
Evotec and Galapagos enter into collaboration in the field of fibrosis/ Evotec en Galapagos gaan samenwerking aan in fibrose
Regulatory Filings Classification · 95% confidence The document is a press release dated February 7, 2019, announcing a collaboration agreement between Evotec and Galapagos regarding a novel target for fibrosis. It details the terms of the agreement (upfront payment, milestones, royalties) and includes standard 'About' sections for both companies and 'Forward-looking statements'. This type of announcement, detailing a strategic partnership, financing terms, or significant business development that is not a standard periodic financial report (like 10-K or IR), best fits the 'Capital/Financing Update' category if it involves significant financial structuring or the 'Regulatory Filings' fallback if it's a general corporate announcement. Since it explicitly details financial arrangements (upfront payment, royalties) related to a strategic asset transfer/collaboration, 'CAP' (Capital/Financing Update) is a strong candidate, although 'RNS' (Regulatory Filings) is often used for press releases announcing deals. Given the focus on the financial structure of the deal, CAP is slightly more specific than the general RNS fallback. However, looking at the definitions, 'CAP' is for fundraising or capital structure changes. This is a collaboration/licensing deal. Since there is no specific category for 'Collaboration Announcement' or 'Licensing Deal', and it is a formal corporate announcement, the most appropriate general category is 'RNS' (Regulatory Filings / General regulatory announcements). It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/director/dividend notice. It is a material corporate event announcement.
2019-02-07 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It references a press release attached as Exhibit 99.1 dated February 7, 2019. The document length is only 2708 characters, which is quite short and primarily serves to submit the press release. There is no substantive financial data or detailed report content within this filing itself. According to the rules, such a short document that mainly attaches or references a press release or report is classified as a Regulatory Filing (RNS), as it does not contain the full report or detailed financial information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-02-07 English
SC 13G Filing
Major Shareholding Notification
2019-01-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.